Arcus Biosciences, Inc. RCUS R2KR3KPHARMA
Company Overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Why Investors Should Care
Revenue has grown at a 48.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $33.00M (-35.3% YoY); net profit $-353.00M.
- Trailing 12 Months Year-on-year growth — revenue -74.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 48.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 48.27% |
| 1 Year: | -74.40% |
Stock Price Performance
| 1 Year: | +194.83% |
| 6 Months: | +34.15% |
| 3 Months: | +27.90% |
| 1 Month: | +4.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 48.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RCUS Arcus Biosciences, Inc. R2KR3KPHARMA | 29.66 | -7.45 | $3.78B | 0.00% | -42.51% | -90.82% | 48.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 1.75M | 1.75M | 1.75M | - | 1.75M | 1.75M | 64.53M | - | 9.46M | 9.46M | 9.46M | 18.00M | 27.00M | 33.00M | 25.00M | 29.00M | 32.00M | 10.00M | 11.00M | 7.00M | 8.00M | 8.00M | 6.00M | 7.00M | 33.00M |
| Operating Income | -7.30M | -9.66M | -23.13M | - | -13.33M | -15.90M | -12.14M | - | -18.77M | -29.16M | -23.25M | - | -28.40M | -45.38M | 1.55M | - | -72.75M | -76.14M | -78.14M | -67.00M | -69.00M | -70.00M | -86.00M | -83.00M | -80.00M | -16.00M | -106.00M | -105.00M | -122.00M | -8.00M | -142.00M | -134.00M | -96.00M |
| Net Income | -7.20M | -9.55M | -23.12M | -13.21M | -12.95M | -13.53M | -10.81M | -12.29M | -17.67M | -28.09M | -22.35M | -16.60M | -27.75M | -45.07M | 1.82M | -51.85M | -72.59M | -75.97M | -77.97M | -68.00M | -67.00M | -65.00M | -80.00M | -75.00M | -71.00M | -4.00M | -93.00M | -92.00M | -112.00M | 0 | -135.00M | -128.00M | -91.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.51 | - | - | - | 0.03 | - | - | - | -1.11 | - | - | -0.90 | -1.09 | -1.04 | -0.94 | -0.05 | -1.02 | -1.00 | -1.14 | 0.00 | -1.27 | -1.02 | -0.72 |
| R&D Expense | 5.80M | 7.83M | 21.43M | - | 11.65M | 13.70M | 12.86M | - | 15.55M | 25.00M | 17.24M | - | 23.14M | 35.69M | 51.80M | - | 66.39M | 68.77M | 71.25M | 61.00M | 70.00M | 77.00M | 81.00M | 84.00M | 82.00M | 109.00M | 115.00M | 123.00M | 122.00M | 139.00M | 141.00M | 122.00M | 113.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.41M | 8.35M | 15.00M | 78.00M | 383.00M | 38.00M | 37.00M | 51.00M | 33.00M |
| Operating Income | -18.18M | -53.44M | -54.86M | -88.71M | -124.00M | 54.00M | -280.00M | -340.00M | -330.00M | -386.00M |
| Net Income | -17.97M | -53.08M | -49.59M | -84.71M | -123.00M | 53.00M | -267.00M | -307.00M | -283.00M | -353.00M |
| Diluted EPS | - | - | - | -1.93 | -2.24 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 |
| R&D Expense | 14.25M | 47.22M | 49.65M | 78.48M | 159.00M | 257.00M | 288.00M | 340.00M | 448.00M | 523.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 190.49M | 274.93M | 203.11M | 772.29M | 1.59B | 1.34B | 1.09B | 1.15B | 1.14B |
| Total Equity | -2.17M | -19.99M | -72.33M | 234.94M | 164.00M | 502.00M | 842.00M | 657.00M | 462.00M | 485.00M | 631.00M |
| Cash & Equivalents | 46.87M | 65.16M | 98.43M | 71.06M | 57.94M | 173.41M | 148.00M | 206.00M | 127.00M | 150.00M | 222.00M |
| Long Term Debt | - | - | - | - | - | - | - | - | 0 | 48.00M | 99.00M |
| Total Liabilities | - | - | 36.62M | 39.98M | 39.27M | 269.99M | 750.45M | - | - | - | - |
| Current Liabilities | - | - | 12.73M | 16.93M | 22.71M | 121.67M | 166.00M | 193.00M | 184.00M | 226.00M | 231.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.94M | -25.06M | -43.00M | -73.46M | 111.00M | - | 438.00M | -306.00M | -170.00M | -482.00M |
| Investing Cash Flow | -38.86M | -49.07M | -113.44M | 59.21M | -434.00M | - | -413.00M | 194.00M | -84.00M | 66.00M |
| Financing Cash Flow | 70.10M | 107.40M | 129.07M | 1.12M | 439.00M | - | 33.00M | 33.00M | 277.00M | 488.00M |
| Capital Expenditure | -4.10M | -5.51M | -3.74M | -1.93M | -3.00M | - | -6.00M | -24.00M | -6.00M | -2.00M |
| Free Cash Flow | -17.04M | -30.57M | -46.74M | -75.39M | 108.00M | - | 432.00M | -330.00M | -176.00M | -484.00M |
| Net Change in Cash | - | - | - | - | - | - | 58.00M | -79.00M | 23.00M | 72.00M |
| Share Buybacks | - | - | 0 | 94.00K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -3,782.1% | -656.8% | -591.4% | -159.0% | 14.1% | -736.8% | -918.9% | -647.1% | -1,169.7% |
| Net Margin % | - | -3,756.7% | -593.7% | -564.7% | -157.7% | 13.8% | -702.6% | -829.7% | -554.9% | -1,069.7% |
| ROE % | 89.9% | 73.4% | -21.1% | -51.7% | -24.5% | 6.3% | -40.6% | -66.5% | -58.4% | -55.9% |
| ROCE % | - | -30.1% | -21.3% | -49.2% | -19.1% | 3.8% | -24.3% | -37.3% | -35.7% | -42.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Gilead Sciences Inc | 24.68% | 31.42M | $917.92M |
| 2 | Blackrock Inc. | 12.89% | 16.42M | $479.52M |
| 3 | State Street Corporation | 4.74% | 6.03M | $176.12M |
| 4 | Wellington Management Group, LLP | 4.63% | 5.90M | $172.21M |
| 5 | Montanova Capital LLC | 3.75% | 4.78M | $139.52M |
| 6 | Vanguard Portfolio Management LLC | 3.51% | 4.48M | $130.73M |
| 7 | FMR, LLC | 3.18% | 4.05M | $118.29M |
| 8 | Vanguard Capital Management LLC | 3.05% | 3.89M | $113.58M |
| 9 | Citadel Advisors Llc | 2.46% | 3.14M | $91.58M |
| 10 | Woodline Partners LP | 2.36% | 3.01M | $87.86M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RCUS
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an inve…
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
CEO Rosen targets casdatifan as $5B to $10B drug with no frontline competition.
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p
Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences (NYSE:RCUS) outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its panc…
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif., August 05, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and a…
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., July 27, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and aut…
RCUS — Frequently Asked Questions
What is the current share price of Arcus Biosciences, Inc. (RCUS)?
As of 2026-09-07 16:24 PDT, Arcus Biosciences, Inc. (RCUS) trades at $29.66 on NYSE. Its 52-week range is $9.91 to $31.57.
What is the market capitalisation of RCUS?
Arcus Biosciences, Inc. (RCUS) has a market capitalisation of $3.78B on NYSE.
What is the P/E ratio of RCUS?
RCUS trades at a trailing price-to-earnings (P/E) ratio of -7.45. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.68.
What is the return on equity (ROE) of RCUS?
RCUS has a return on equity (ROE) of -90.82%. Its return on capital employed (ROCE) is -42.51%.
Is RCUS a good stock to buy?
This page provides a data-driven analysis of Arcus Biosciences, Inc. (RCUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.